H
HaTay Pharmaceutical JSC
VN:DHT
HaTay Pharmaceutical JSC
VN:DHT
Price:
69 200
VND
0.29%
Market Closed
Market Cap:
₫6.3T
Relative Value
The Relative Value of one DHT stock under the Base Case scenario is 41 387.38 VND. Compared to the current market price of 69 200 VND, HaTay Pharmaceutical JSC is Overvalued by 40%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DHT
Relative Value
Base Case
41 387.38
VND
Overvaluation 40%
H
Multiples Across Competitors
DHT Competitors Multiples
HaTay Pharmaceutical JSC Competitors
HaTay Pharmaceutical JSC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| VN |
H
|
HaTay Pharmaceutical JSC
VN:DHT
|
6.3T VND | 2.6 | 116.8 | 156.4 | 156.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD | 14.3 | 45.2 | 30.5 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF | 4.4 | 21 | 12.4 | 13.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.7 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 2.5 | 17.2 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
